Cargando…
The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
The prognostic value of the cumulative cisplatin dose (CCD) remains controversial for patients with nasopharyngeal carcinoma (NPC) receiving only concurrent chemoradiotherapy (CCRT). We retrospectively reviewed 549 consecutive patients with non-metastatic, histologically-proven NPC treated using int...
Autores principales: | Peng, Hao, Chen, Lei, Li, Wen-Fei, Guo, Rui, Mao, Yan-Ping, Zhang, Yuan, Zhang, Fan, Liu, Li-Zhi, Tian, Li, Lin, Ai-Hua, Sun, Ying, Ma, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829825/ https://www.ncbi.nlm.nih.gov/pubmed/27071833 http://dx.doi.org/10.1038/srep24332 |
Ejemplares similares
-
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
por: Lv, Jia‐Wei, et al.
Publicado: (2018) -
Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021) -
Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand
por: Ngamphaiboon, Nuttapong, et al.
Publicado: (2020) -
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2015) -
Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy
por: Wang, Jun, et al.
Publicado: (2022)